Analysis of liver cancer development in patients who showed sustained viral response to chronic hepatitis C virus infection by receiving direct acting-antiviral therapy, a prospective multicenter study

Analysis of liver cancer development in patients who showed sustained viral response to chronic hepatitis C virus infection by receiving direct acting-antiviral therapy, a prospective multicenter study - A prospective multicenter study on hepatocarcinogenesis after DAA-induced SVR for HCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027988

Enrollment

2000

Registered

2017-07-03

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C virus-related chronic liver diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20 years old of age or more 2) HCVRNA-positive results prior to DAA treatment 3) Curative treatment for patients who had HCC 4) Informed consent for DAA treatments 5) Eligible for each DAA used in this study

Exclusion criteria

Exclusion criteria: 1) (Potentially) pregnant woman and lactating woman 2) Allergic reaction for DAAs and biological agents including vaccines 3) Difficult-to-control heart diseases 4) Severe liver injury, including Child-Pugh class B and C 5) Contraindicated drugs for combination with DAAs 6) Uncontrolled diabetes mellitus 7) Inappropriate patients who are judged by study-managing doctors

Design outcomes

Primary

Measure	Time frame
Characteristics of liver cancer developed after DAA-induced SVR (tumor size, number of tumor, gross appearance, location, vascular invasion, and tumor markers)	—

Secondary

Measure	Time frame
1) Patient characteristics and background liver when liver caner occurs 2) Liver cancer incidence 3)Possible inhibitory effect of SVR on liver cancer recurrence in patients receiving curative therapy for primary liver cancer 4) Patients' prognosis 5) Adverse effects of DAA treatments	—

Countries

Japan

Contacts

Public ContactHironori Koga

Kurume University School of Medicine Division of Gastroenterology, Department of Medicine

hirokoga@med.kurume-u.ac.jp0942-31-7746

Outcome results